FDA decision may make Chagas treatment even more expensive
A biopharmaceutical company has permission from the U.S. Food and Drug Administration (FDA) to fast-track the approval process for benznidazole, a drug used to treat Chagas disease, raising concern that the drug would become even more inaccessible for vulnerable populations across Latin America.
